Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy

Blood Adv. 2023 Jun 27;7(12):2825-2830. doi: 10.1182/bloodadvances.2022009480.

Authors

Brittany M Lee^{1

2}, Corinne Summers^{2

3}, Karen M Chisholm^{4

5}, Sandra D Bohling^{4

5}, Kasey J Leger^{1

2}, Rebecca Gardner^{1

2}, Colleen Annesley^{1

2}, Adam J Lamble^{1

2}

Affiliations

¹ Seattle Children's Research Institute, Seattle, WA.
² Department of Pediatrics, University of Washington School of Medicine, University of Washington, Seattle, WA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
⁴ Department of Laboratories, Seattle Children's Hospital, Seattle, WA.
⁵ Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, University of Washington, Seattle, WA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD19
Burkitt Lymphoma*
Humans
Immunotherapy

Substances

Antigens, CD19